Membranous glomerulonephritis diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
| Line 14: | Line 14: | ||
== Diagnostic Study of Choice == | == Diagnostic Study of Choice == | ||
=== Gold standard/Study of choice: ===<ref name="pmid22956816">{{cite journal |vauthors=Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF |title=Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy |journal=J. Am. Soc. Nephrol. |volume=23 |issue=10 |pages=1735–43 |date=October 2012 |pmid=22956816 |pmc=3458465 |doi=10.1681/ASN.2012030242 |url=}}</ref> <ref name="pmid21566055">{{cite journal |vauthors=Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z |title=Anti-phospholipase A2 receptor antibody in membranous nephropathy |journal=J. Am. Soc. Nephrol. |volume=22 |issue=6 |pages=1137–43 |date=June 2011 |pmid=21566055 |pmc=3103733 |doi=10.1681/ASN.2010090967 |url=}}</ref> <ref name="pmid22956816">{{cite journal |vauthors=Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF |title=Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy |journal=J. Am. Soc. Nephrol. |volume=23 |issue=10 |pages=1735–43 |date=October 2012 |pmid=22956816 |pmc=3458465 |doi=10.1681/ASN.2012030242 |url=}}</ref> | === Gold standard/Study of choice: === | ||
* Biopsy is the gold standard test for the diagnosis of membranous glomerulonephritis.<ref name="pmid22956816">{{cite journal |vauthors=Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF |title=Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy |journal=J. Am. Soc. Nephrol. |volume=23 |issue=10 |pages=1735–43 |date=October 2012 |pmid=22956816 |pmc=3458465 |doi=10.1681/ASN.2012030242 |url=}}</ref> <ref name="pmid21566055">{{cite journal |vauthors=Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z |title=Anti-phospholipase A2 receptor antibody in membranous nephropathy |journal=J. Am. Soc. Nephrol. |volume=22 |issue=6 |pages=1137–43 |date=June 2011 |pmid=21566055 |pmc=3103733 |doi=10.1681/ASN.2010090967 |url=}}</ref> <ref name="pmid22956816">{{cite journal |vauthors=Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF |title=Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy |journal=J. Am. Soc. Nephrol. |volume=23 |issue=10 |pages=1735–43 |date=October 2012 |pmid=22956816 |pmc=3458465 |doi=10.1681/ASN.2012030242 |url=}}</ref> | |||
<ref name="pmid24021909">{{cite journal |vauthors=Timmermans SA, Ayalon R, van Paassen P, Beck LH, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW |title=Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy |journal=Am. J. Kidney Dis. |volume=62 |issue=6 |pages=1223–5 |date=December 2013 |pmid=24021909 |doi=10.1053/j.ajkd.2013.07.019 |url=}}</ref><ref name="pmid27777266">{{cite journal |vauthors=De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC |title=A Proposal for a Serology-Based Approach to Membranous Nephropathy |journal=J. Am. Soc. Nephrol. |volume=28 |issue=2 |pages=421–430 |date=February 2017 |pmid=27777266 |pmc=5280030 |doi=10.1681/ASN.2016070776 |url=}}</ref> | <ref name="pmid24021909">{{cite journal |vauthors=Timmermans SA, Ayalon R, van Paassen P, Beck LH, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW |title=Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy |journal=Am. J. Kidney Dis. |volume=62 |issue=6 |pages=1223–5 |date=December 2013 |pmid=24021909 |doi=10.1053/j.ajkd.2013.07.019 |url=}}</ref><ref name="pmid27777266">{{cite journal |vauthors=De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC |title=A Proposal for a Serology-Based Approach to Membranous Nephropathy |journal=J. Am. Soc. Nephrol. |volume=28 |issue=2 |pages=421–430 |date=February 2017 |pmid=27777266 |pmc=5280030 |doi=10.1681/ASN.2016070776 |url=}}</ref> | ||
* The complete blood count, urinalysis, 24 hour urine collection should be performed when: | * The complete blood count, urinalysis, 24 hour urine collection should be performed when: | ||
** The patient presented with signs of proteinurea and hypertension. | ** The patient presented with signs of proteinurea and hypertension. | ||
Revision as of 14:02, 16 July 2018
|
Membranous glomerulonephritis Microchapters |
|
Differentiating Membranous glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranous glomerulonephritis diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Membranous glomerulonephritis diagnostic study of choice |
|
FDA on Membranous glomerulonephritis diagnostic study of choice |
|
CDC on Membranous glomerulonephritis diagnostic study of choice |
|
Membranous glomerulonephritis diagnostic study of choice in the news |
|
Blogs on Membranous glomerulonephritis diagnostic study of choice |
|
Directions to Hospitals Treating Membranous glomerulonephritis |
|
Risk calculators and risk factors for Membranous glomerulonephritis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
- The page name should be "[Disease name] diagnostic study of choice", with only the first letter of the title capitalized. Note that the page is called "Diagnostic study of choice."
- Goal:
- To describe the most efficient/sensitive/specific test that is utilized for diagnosis of [disease name].
- To describe the gold standard test for the diagnosis of [disease name].
- To describe the diagnostic criteria, which may be based on clinical findings, physical exam signs, pathological findings, lab findings, findings on imaging, or even findings that exclude other diseases.
- As with all microchapter pages linking to the main page, at the top of the edit box put {{CMG}}, your name template, and the microchapter navigation template you created at the beginning.
- Remember to create links within WikiDoc by placing [[square brackets]] around key words which you want to link to other pages. Make sure you makes your links as specific as possible. For example, if a sentence contained the phrase anterior spinal artery syndrome, the link should be to anterior spinal artery syndrome not anterior or artery or syndrome. For more information on how to create links, click here.
- Remember to follow the same format and capitalization of letters as outlined in the template below.
- You should include the name of the disease in the first sentence of every subsection.
Diagnostic Study of Choice
Gold standard/Study of choice:
- The complete blood count, urinalysis, 24 hour urine collection should be performed when:
- The patient presented with signs of proteinurea and hypertension.
- A positive [test] is detected in the patient.
- Biopsy is the gold standard test for the diagnosis of membranous glomerulonephritis.
The diagnostic study of choice for membranous glomerulonephritis are:
- chemistry panel,
- complete blood count,
- urinalysis,
- 24 hours urine collection,
- creatinine clearance,
- urine albumin,
- ANA,
- anti-doublestandard DNA,
- anti-SM,
- anti Ro/SSA,
- anti La/SSB,
- serum C3 and C4 Complement levels.
- Chest CT,
- Anti PLA2Rantibody.
Diagnostic Test:
Biopsy is confirmatory of membranous glomerulonephritis.
Sequence of Diagnostic Studies
The urinalysis and comprehensive chemistry panel should be performed when:
- The patient presented with signs of hypertension and proteinurea.
- A positive ANA, anti dsDNA is detected in the patient, to confirm the diagnosis.
Diagnostic Criteria
- There are no established criteria for the diagnosis of membranous glomerulonephritis.
References
- ↑ 1.0 1.1 Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF (October 2012). "Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy". J. Am. Soc. Nephrol. 23 (10): 1735–43. doi:10.1681/ASN.2012030242. PMC 3458465. PMID 22956816.
- ↑ Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z (June 2011). "Anti-phospholipase A2 receptor antibody in membranous nephropathy". J. Am. Soc. Nephrol. 22 (6): 1137–43. doi:10.1681/ASN.2010090967. PMC 3103733. PMID 21566055.
- ↑ Timmermans SA, Ayalon R, van Paassen P, Beck LH, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW (December 2013). "Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy". Am. J. Kidney Dis. 62 (6): 1223–5. doi:10.1053/j.ajkd.2013.07.019. PMID 24021909.
- ↑ De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC (February 2017). "A Proposal for a Serology-Based Approach to Membranous Nephropathy". J. Am. Soc. Nephrol. 28 (2): 421–430. doi:10.1681/ASN.2016070776. PMC 5280030. PMID 27777266.